KZR - Bullish Divergence Found. Possible Change In Momentum

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which discovers and develops novel small molecule therapeutics to treat autoimmunity and cancer. The firm specializes in the areas of protein degradation and protein secretion to discover & develop novel therapies for the treatment of serious and unmet medical needs. Its product include KZR-616, an immunoproteasome inhibitor, has completed testing in healthy volunteers. The company was founded by John Fowler, Christopher J. Kirk and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.

SHORT INTEREST
1.12M 08/15/19

P/E Current
-1.50

P/E Ratio (with extraordinary items)
-2.32

Average Recommendation: BUY

Average Target Price: 24.33